EUVIMEDEUVIMED entdecken
Crossref

Neddylation inhibition sensitizes gastric cancer to 5-fluorouracil by targeting the post-translational stability of the metabolic enzyme dihydropyrimidine dehydrogenase

Qianqian Zhang, Jingyi Hu, Yangbo Liu, Dongzhao Xie, Linyue Bai, Zhuang Hu, Yanjun Tang, Siqi Feng

Drug Metabolism and Disposition · 2026-04 · 54 (4) · 100274

DOI: 10.1016/j.dmd.2026.100274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-04. Verfasst von Qianqian Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou, Chi…. Hauptthemen laut MEDLINE: Fluorouracil, Stomach Neoplasms, Pyrimidines, Cyclopentanes. Die Arbeit nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Henan Provincial Science and Technology Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic efficacy of 5-fluorouracil (5-FU), a cornerstone of gastric cancer chemotherapy, is predominantly limited by its catabolic inactivation in tumors. Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme responsible for 5-FU inactivation, and its tumor-specific overexpression constitutes a primary mechanism of 5-FU resistance. Here, we report a novel strategy to increase the sensitivity of 5-FU by targeting the post-translational regulation of DPD. We demonstrate that the neural precursor cell expressed, developmentally downregulated 8-activating enzyme (NAE) inhibitor MLN4924 significantly enhances the antitumor activity of 5-FU in both cellular and animal models of gastric cancer without augmenting systemic toxicity. Mechanistically, MLN4924 treatment inhibits the neddylation of DPD, which is dependent on the NAE1/ubiquitin-conjugating enzyme 12 axis. This inhibition triggers the ubiquitination and subsequent proteasomal degradation of DPD, thereby reducing intracellular 5-FU catabolism and augmenting its cytotoxic effects. Our findings identify neddylation as a previously unrecognized regulatory mechanism governing DPD protein stability and activity. This work identifies the neddylation-DPD axis as a novel therapeutic target and provides a strong rationale for combining NAE inhibition with 5-FU-based chemotherapy in gastric cancer. SIGNIFICANCE STATEMENT: This study establishes neddylation as a previously unrecognized regulatory mechanism that stabilizes the drug-metabolizing enzyme dihydropyrimidine dehydrogenase to drive 5-fluorouracil resistance in gastric cancer. It further unveils that inhibiting neddylation with MLN4924 selectively depletes tumor dihydropyrimidine dehydrogenase, enhancing chemotherapy efficacy without increasing toxicity, thereby proposing a targeted strategy to overcome chemoresistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluorouracilStomach NeoplasmsPyrimidinesCyclopentanesDihydrouracil Dehydrogenase (NADP)Protein Processing, Post-TranslationalNEDD8 ProteinAnimalsHumansCell Line, TumorMiceUbiquitin-Activating EnzymesDrug Resistance, NeoplasmUbiquitinationXenograft Model Antitumor Assays

Stichwörter der Autor:innen

5-FluorouracilDihydropyrimidine dehydrogenaseGastric cancerNeddylationUBC12

Substanzen

FluorouracilpevonedistatPyrimidinesCyclopentanesDihydrouracil Dehydrogenase (NADP)NEDD8 ProteinNAE protein, humanUbiquitin-Activating Enzymes

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou, China.
  • School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou, China; Department of Pharmacy, Nanshi Hospital of Nanyang, Nanyang, China.
  • School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou, China. Electronic address: fsq1212@zzu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Henan Provincial Science and Technology Research Project

Zitieren

APA

Zhang, Q., Hu, J., Liu, Y., Xie, D., Bai, L., Hu, Z., Tang, Y., & Feng, S. (2026). Neddylation inhibition sensitizes gastric cancer to 5-fluorouracil by targeting the post-translational stability of the metabolic enzyme dihydropyrimidine dehydrogenase. Drug Metabolism and Disposition, 54(4), 100274. https://doi.org/10.1016/j.dmd.2026.100274

Vancouver

Zhang Q, Hu J, Liu Y, Xie D, Bai L, Hu Z, et al. Neddylation inhibition sensitizes gastric cancer to 5-fluorouracil by targeting the post-translational stability of the metabolic enzyme dihydropyrimidine dehydrogenase. Drug Metabolism and Disposition. 2026;54(4):100274. doi:10.1016/j.dmd.2026.100274

BibTeX
@article{Zhang2026,
  author = {Zhang, Qianqian and Hu, Jingyi and Liu, Yangbo and Xie, Dongzhao and Bai, Linyue and Hu, Zhuang and Tang, Yanjun and Feng, Siqi},
  title = {Neddylation inhibition sensitizes gastric cancer to 5-fluorouracil by targeting the post-translational stability of the metabolic enzyme dihydropyrimidine dehydrogenase},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {4},
  pages = {100274},
  doi = {10.1016/j.dmd.2026.100274}
}
Kostenlos starten →